About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
66 y/o Male With DLBCL: R-CHOP, Revlimid Upfront, Curative Options, R-GemOx, CAR-T, Relapse After ASCT
By
Virtual West Oncology Conference
FEATURING
Jason Chandler
,
Neha Mehta-Shah
,
Abdulraheem Yacoub
,
Carlos Bachier
By
Virtual West Oncology Conference
FEATURING
Jason Chandler
,
Neha Mehta-Shah
,
Abdulraheem Yacoub
,
Carlos Bachier
17 views
March 11, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
13:07
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
Feat.
J. Chavez
09:18
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…
Feat.
J. Westin
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
Feat.
R. Gale
08:23
Total Health
R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment
Feat.
J. Chandler,
B. Randolph,
M. Onciu
22:09
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024
New Updates in Frontline DLCBL
Feat.
L. Nastoupil
08:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…
Feat.
R. Bansal
04:08
GRACE
CAR T-Cell Therapy Side Effects for Blood Cancers
Feat.
A. Goodman
62:02
UChicago Medicine
New Treatment Strategies in DLBCL
Feat.
L. Sehn
09:45
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary …
Feat.
M. Kamdar
15:26
Moffitt Cancer Center
R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?
Feat.
A. Lazaryan
16:03
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: The New Algorithm for 2L LBCL
Feat.
J. Westin
32:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
The Improbable History of CAR T-Cells
Feat.
C. June
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
15:33
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…
Feat.
J. Friedberg
10:27
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Rates of CRS and ICANS From CIBMTR Data o…
Feat.
J. DiPersio
25:44
Tara Graff
DLBCL Updates From iCML 2023
07:06
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…
Feat.
L. Shune
06:09
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Outcomes of Pts With Richter's Transfo…
Feat.
A. Kittai
